Yes this is the major point. Previously we had data that Bisantrene performed just as well as doxorubicin (but was safer to the heart), we now have evidence that Bisantrene works better than doxorubicin in drug resistant patients (i.e. late stage metastatic patients). It is much easier to get a drug approved (and sell) that both works better and is safer.
Ann: Compelling Preclinical Breast Cancer Results, page-53
-
- There are more pages in this discussion • 201 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add RAC (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.86 |
Change
-0.080(4.12%) |
Mkt cap ! $315.1M | |||
| Open | High | Low | Value | Volume |
| $1.95 | $1.95 | $1.84 | $367.9K | 195.0K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 244 | $1.86 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.87 | 2000 | 1 |
View Market Depth
| Last trade - 12.33pm 15/07/2024 (20 minute delay) ? |
| RAC (ASX) Chart |